Dr. Nathan L. Bennett, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1990)
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 89
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1990Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
PA license MD-047370L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- Jefferson Hospital Jefferson Hills, PA
Medical groups
- Preferred Primary Care Physicians, Inc. (88 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 89
- Services billed
- 8,564
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 8,375 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 159 | 72 |
| Established patient office or other outpatient visit, 20-29 minutes | 128 | 63 |
| Insertion of needle into vein for collection of blood sample | 107 | 57 |
| Annual depression screening, 5 to 15 minutes | 66 | 62 |
| Blood test, comprehensive group of blood chemicals | 64 | 48 |
| Blood test, lipids (cholesterol and triglycerides) | 60 | 46 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 50 | 35 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 42 | 42 |
| Creatinine level to test for kidney function or muscle injury | 39 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 91 payments worth $34,428 in total to this clinician.
| AbbVie Inc. | $25,435 |
|---|---|
| Pfizer Inc. | $6,157 |
| Axsome Therapeutics, Inc. | $2,066 |
| Ipsen Innovation | $472 |
| Lundbeck LLC | $206 |
| Novo Nordisk Inc | $54.81 |
| Abbott Laboratories | $22.13 |
| Tonix Medicines, Inc. | $16.14 |
| Compensation for services other than consulting (speaking, faculty) | $15,188 |
|---|---|
| Consulting Fee | $13,413 |
| Food and Beverage | $1,990 |
| Honoraria | $1,925 |
| Travel and Lodging | $1,913 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 9, 2025 | Consulting Fee QULIPTA · NEUROSCIENCE | $8,594 |
| Pfizer Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,625 |
| AbbVie Inc. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $3,125 |
| AbbVie Inc. Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,125 |
| Axsome Therapeutics, Inc. Nov 18, 2025 | Honoraria Symbravo · Neurology | $1,925 |
| AbbVie Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $1,875 |
| AbbVie Inc. Aug 5, 2025 | Consulting Fee QULIPTA · NEUROSCIENCE | $1,875 |
| AbbVie Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $1,875 |
| AbbVie Inc. Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $1,563 |
| Pfizer Inc. Sep 24, 2025 | Consulting Fee NURTEC ODT · PAIN | $1,225 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 9, 2025 | Consulting Fee QULIPTA · NEUROSCIENCE | $8,594 |
| AbbVie Inc. Dec 9, 2025 | Consulting Fee QULIPTA · NEUROSCIENCE | $938 |
| AbbVie Inc. Nov 19, 2025 | Consulting Fee UBRELVY · NEUROSCIENCE | $313 |
| Axsome Therapeutics, Inc. Nov 18, 2025 | Honoraria Symbravo · Neurology | $1,925 |
| AbbVie Inc. Nov 15, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to DENVER, CO · in-kind | $337 |
| AbbVie Inc. Nov 14, 2025 | Travel and Lodging BOTOX · NEUROSCIENCE · travel to DENVER, CO · in-kind | $335 |
| AbbVie Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $1,875 |
| Pfizer Inc. Oct 1, 2025 | Travel and Lodging NURTEC ODT · PAIN · travel to Indiana, PA · in-kind | $1,006 |
| Pfizer Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) NURTEC ODT · PAIN | $3,625 |
| Pfizer Inc. Sep 24, 2025 | Consulting Fee NURTEC ODT · PAIN | $1,225 |
| AbbVie Inc. Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $3,125 |
| AbbVie Inc. Aug 7, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA · NEUROSCIENCE | $1,563 |
| AbbVie Inc. Aug 5, 2025 | Consulting Fee QULIPTA · NEUROSCIENCE | $1,875 |
| AbbVie Inc. Jul 2, 2025 | Consulting Fee BOTOX · FACIAL AESTHETICS | $469 |
| AbbVie Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $1,875 |
| Ipsen Innovation Jun 17, 2025 | Travel and Lodging travel to Minneapolis, MN · in-kind | $236 |
| AbbVie Inc. Jan 28, 2025 | Compensation for services other than consulting (speaking, faculty) QULIPTA; UBRELVY · NEUROSCIENCE | $3,125 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $124,184 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Ipsen Innovation · Active, not recruiting · NCT06625060 - A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications
H. Lundbeck A S - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
AbbVie Inc. · Completed · NCT05216263 - M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
AbbVie Inc. - A phase 4 randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of rimegepant in episodic migraine prevention with multiple dosing regimens
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.